Compare Neurocrine Biosciences Inc (NBIX) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs AT&T Inc. — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while AT&T Inc. trades at $23.23 (market cap $167.68B). The key difference: AT&T Inc. is far larger — about 11.5× Neurocrine Biosciences Inc's market cap, and AT&T Inc. pays a 4.54% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and AT&T Inc. for 118 Days on average.
| NBIX | T | |
|---|---|---|
Market Cap | $14.60B | $167.68B |
Volume | 1,075,694 | 27,788,850 |
Sector | Health | Media |
52-Week High | $185.50 | $29.10 |
52-Week Low | $123.10 | $20.49 |
Typical Hold Time | 23 Days | 118 Days |
Enterprise Value | $14.61B | $313.00B |
Dividend Yield | — | 4.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
AT&T (T) trades at $24.885, up 1.88% in the last session, with a bearish technical signal but strong fundamentals including a P/E of 8.08 and net income margin of 16.94%. Recent earnings beats and a $3 billion fiber deal with Corning highlight growth initiatives, while cash flow improved to $15.12B in 2025.
The stock offers value with a 4%+ dividend yield and analyst consensus price target of $27.61, but faces risks from high debt and competitive pressures. Upside depends on execution in fiber and wireless, while sentiment is mixed amid dividend sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
